Alzinova AB (publ) (STO:ALZ)
0.4950
-0.0300 (-5.71%)
May 21, 2026, 12:42 PM CET
Alzinova AB Revenue
Alzinova AB had revenue of 4.95M SEK in the quarter ending March 31, 2026, a decrease of -18.82%. This brings the company's revenue in the last twelve months to 25.66M, up 27.95% year-over-year. In the year 2025, Alzinova AB had annual revenue of 26.80M with 59.44% growth.
Revenue (ttm)
25.66M
Revenue Growth
+27.95%
P/S Ratio
3.17
Revenue / Employee
3.67M
Employees
7
Market Cap
81.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.80M | 9.99M | 59.44% |
| Dec 31, 2024 | 16.81M | -3.06M | -15.41% |
| Dec 31, 2023 | 19.87M | 3.24M | 19.49% |
| Dec 31, 2022 | 16.63M | -688.74K | -3.98% |
| Dec 31, 2021 | 17.32M | 2.42M | 16.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IRLAB Therapeutics AB | 92.46M |
| Fluicell AB | 20.06M |
| Scandinavian ChemoTech AB | 12.61M |
| Biovica International AB | 10.93M |
| AcouSort AB | 10.43M |
| Spago Nanomedical AB | 4.38M |
| OncoZenge AB | 2.78M |
| 2cureX AB | 1.98M |
Alzinova AB News
- 8 days ago - Alzinova AB Quarterly report: Q1 2026 - Filings
- 2 months ago - Alzinova AB Quarterly report: Q4 2025 - Filings
- 2 months ago - Alzinova AB Annual report: Q4 2025 - Filings
- 6 months ago - Alzinova AB Quarterly report: Q3 2025 - Filings
- 8 months ago - Alzinova AB Transcript: Investing in Life Science 2025 - Transcripts
- 9 months ago - Alzinova AB Quarterly report: Q2 2025 - Filings